IL122642A0 - Substituted purine derivatives processes for their preparation their use and compositions comprising them - Google Patents

Substituted purine derivatives processes for their preparation their use and compositions comprising them

Info

Publication number
IL122642A0
IL122642A0 IL12264297A IL12264297A IL122642A0 IL 122642 A0 IL122642 A0 IL 122642A0 IL 12264297 A IL12264297 A IL 12264297A IL 12264297 A IL12264297 A IL 12264297A IL 122642 A0 IL122642 A0 IL 122642A0
Authority
IL
Israel
Prior art keywords
compositions
preparation
purine derivatives
substituted purine
derivatives processes
Prior art date
Application number
IL12264297A
Other languages
English (en)
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of IL122642A0 publication Critical patent/IL122642A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12264297A 1996-12-20 1997-12-18 Substituted purine derivatives processes for their preparation their use and compositions comprising them IL122642A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (de) 1996-12-20 1996-12-20 Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung

Publications (1)

Publication Number Publication Date
IL122642A0 true IL122642A0 (en) 1998-08-16

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12264297A IL122642A0 (en) 1996-12-20 1997-12-18 Substituted purine derivatives processes for their preparation their use and compositions comprising them

Country Status (22)

Country Link
EP (1) EP0853084B1 (ru)
JP (1) JP4620190B2 (ru)
KR (1) KR19980064655A (ru)
CN (2) CN1495184A (ru)
AR (1) AR010700A1 (ru)
AT (1) ATE404562T1 (ru)
AU (1) AU728865B2 (ru)
BR (1) BR9706387A (ru)
CA (1) CA2225366C (ru)
CZ (1) CZ294437B6 (ru)
DE (2) DE19653646A1 (ru)
HK (1) HK1012190A1 (ru)
HU (1) HUP9702507A3 (ru)
ID (1) ID19254A (ru)
IL (1) IL122642A0 (ru)
NO (1) NO314583B1 (ru)
NZ (1) NZ329431A (ru)
PL (1) PL323969A1 (ru)
RU (1) RU2228335C2 (ru)
TR (1) TR199701647A3 (ru)
TW (1) TW523515B (ru)
ZA (1) ZA9711317B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE542797T1 (de) 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten
CZ20012321A3 (cs) 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a inhibitoru matricové metaloproteinázy pro kombinační terapii při léčení neoplasie
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
KR100438820B1 (ko) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Ιιι-ⅴ족 화합물 반도체 기판의 제조 방법
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
KR101534884B1 (ko) 2007-10-11 2015-07-08 다이이찌 산쿄 가부시키가이샤 파골 세포 관련 단백질 Ｓｉｇｌｅｃ-15 를 표적으로 한 항체
JP2011503206A (ja) * 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
KR101690340B1 (ko) 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 항 Ｓｉｇｌｅｃ-15 항체
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
KR20150003170A (ko) 2012-03-30 2015-01-08 다이이찌 산쿄 가부시키가이샤 ＣＤＲ 개변 항 Ｓｉｇｌｅｃ-15 항체
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (ru) * 1966-12-10 1972-09-13
JPS6396663A (ja) * 1986-10-13 1988-04-27 Mita Ind Co Ltd 静電荷像現像用トナ−
JPS6396553A (ja) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd 充填剤
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
FR2700337B1 (fr) * 1993-01-11 1995-04-14 Lafon Labor Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
PL318199A1 (en) * 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
AU4729796A (en) * 1994-12-28 1996-07-19 Peter E. Nielsen Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
WO1996040709A1 (en) * 1995-06-07 1996-12-19 Perseptive Biosystems, Inc. Pna-dna chimeras and pna synthons for their preparation
JPH1025294A (ja) * 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
NZ331647A (en) * 1996-03-26 2000-03-27 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69734783T2 (de) * 1996-07-24 2006-08-17 Buchardt, Dorte Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
ID19254A (id) 1998-06-28
NO314583B1 (no) 2003-04-14
AU4846697A (en) 1998-06-25
JPH10182645A (ja) 1998-07-07
TW523515B (en) 2003-03-11
BR9706387A (pt) 2000-03-14
EP0853084A3 (de) 1998-09-09
AR010700A1 (es) 2000-06-28
TR199701647A2 (xx) 1998-07-21
KR19980064655A (ko) 1998-10-07
CZ294437B6 (cs) 2005-01-12
MX9710277A (es) 1998-10-31
RU2228335C2 (ru) 2004-05-10
EP0853084B1 (de) 2008-08-13
ATE404562T1 (de) 2008-08-15
AU728865B2 (en) 2001-01-18
TR199701647A3 (tr) 1998-07-21
CN1193623A (zh) 1998-09-23
CA2225366A1 (en) 1998-06-20
CZ411497A3 (cs) 1998-07-15
HU9702507D0 (en) 1998-03-02
HK1012190A1 (en) 1999-07-30
EP0853084A2 (de) 1998-07-15
HUP9702507A2 (hu) 1999-05-28
DE59712958D1 (de) 2008-09-25
CN1101816C (zh) 2003-02-19
CN1495184A (zh) 2004-05-12
HUP9702507A3 (en) 1999-12-28
PL323969A1 (en) 1998-06-22
NZ329431A (en) 2000-01-28
ZA9711317B (en) 1998-06-22
NO975977D0 (no) 1997-12-19
NO975977L (no) 1998-06-22
DE19653646A1 (de) 1998-06-25
JP4620190B2 (ja) 2011-01-26
CA2225366C (en) 2006-10-10

Similar Documents

Publication Publication Date Title
IL122642A0 (en) Substituted purine derivatives processes for their preparation their use and compositions comprising them
AP9901556A0 (en) Sulpponamide derivatives process for their preparation and their use as medicaments
HK1016580A1 (en) Purine derivatives and processes for their preparation
ZA968322B (en) Solid sillicone compositions and methods for their preparation and use
GB2326093B (en) Avermectin formulation
AP9801369A0 (en) Dispersible macromole-cule compositions and methods for their preparation and use
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
HK1112180A1 (en) Pharmaceutical use and compositions involving isoflavones
IL116066A0 (en) Controlled release caffeine composition and its preparation
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
IL126381A (en) Heterocyclic azahexane derivatives and antiviral compositions containing them
IL114795A0 (en) N-benzylindole- and benmzopyrazole derivatives their preparation and use
IL136308A0 (en) Antipicornaviral compounds and methods for their use and preparation
IL129089A0 (en) New derivatives from piperidine-keto acid their preparation and use
IL125710A0 (en) Arylglycinamide derivatives their preparation and pharmaceutical compositions containing them
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
GB2327190B (en) Process for the preparation of depilatory compositions and their use
ZA973097B (en) Novel aspire-hydroxy acid derivatives their preparation and use
IL117623A (en) Maltitol composition and its preparation
GB9705035D0 (en) Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
IL118443A0 (en) Cycloalkane-benzylidene derivatives their preparation and use
IL125149A (en) Pyrazol-4-yl-hetaroyl derivatives their preparation and herbicidal compositions comprising them
IL121691A0 (en) N-benzylazolium derivatives their preparation and compositions containing them
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
HK1015763A1 (en) Benzoxazindione derivatives, process for their preparation and their use